AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
As of today, AbbVie(ABBV) shares are valued at $225.00. The company's market cap stands at 397.93B, with a P/E ratio of 168.26 and a dividend yield of 2.9%.
On 2025-12-10, AbbVie(ABBV) stock moved within a range of $221.00 to $225.98. With shares now at $225.00, the stock is trading +1.8% above its intraday low and -0.4% below the session's peak.
Trading volume for AbbVie(ABBV) stock has reached 8.5M, versus its average volume of 4.69M.
Over the past 52 weeks, AbbVie(ABBV) stock has traded between a high of $244.81 and a low of $164.39.
Over the past 52 weeks, AbbVie(ABBV) stock has traded between a high of $244.81 and a low of $164.39.
ABBV News
This Dividend Pharma Giant Yielding 2.9% Just Got a Big Vote of Confidence Quick Read AbbVie ( ABBV ) is up 25% year-to-date and doubled the S&P 500 ‘s return....
Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More...
HSBC upgraded AbbVie (ABBV) to Buy from Hold with a price target of $265, up from $225. The company is seeing growth momentum and its execution should remain so...
Analyst ratings
71%
of 31 ratingsMore ABBV News
Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model ba...
Key Points AbbVie's third-quarter results exceeded Wall Street's expectations. Sales from the pharmaceutical company's three top drugs are soaring. 10 stocks...
In recent weeks AbbVie has reported positive late-stage trial results for migraine drug atogepant, advanced oncology assets including PVEK for rare blood cancer...
Don't bet against it. One effective way to earn solid, long-term returns is to invest in dividend-paying stocks since reinvesting the payout can help boost sto...
